Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.
(2009) In BJU International 104. p.10-18- Abstract
- The treatment of metastatic renal cell carcinoma (mRCC) has been changed by the introduction of targeted agents. Consideration of individual patient factors, such as previous treatment and prognostic risk, e.g. according to the Memorial Sloan-Kettering Cancer Center (MSKCC) risk criteria), can assist in ensuring that patients receive appropriate targeted therapies. Available clinical evidence shows sunitinib to be the reference standard of care for the first-line treatment of mRCC in patients at favourable or intermediate prognostic risk according to MSKCC criteria. Combined treatment with bevacizumab plus interferon-alpha can also be considered for the first-line treatment of mRCC in this setting. For the first-line treatment of poor-risk... (More)
- The treatment of metastatic renal cell carcinoma (mRCC) has been changed by the introduction of targeted agents. Consideration of individual patient factors, such as previous treatment and prognostic risk, e.g. according to the Memorial Sloan-Kettering Cancer Center (MSKCC) risk criteria), can assist in ensuring that patients receive appropriate targeted therapies. Available clinical evidence shows sunitinib to be the reference standard of care for the first-line treatment of mRCC in patients at favourable or intermediate prognostic risk according to MSKCC criteria. Combined treatment with bevacizumab plus interferon-alpha can also be considered for the first-line treatment of mRCC in this setting. For the first-line treatment of poor-risk patients, temsirolimus has shown benefit in a phase III study, while sunitinib can also be considered. For second-line treatment in cytokine-refractory patients, sorafenib is recommended based on phase III trial results; sunitinib has also shown activity after failure of cytokine therapy or targeted agents. As well as antitumour activity, the tolerability of targeted agents should be evaluated in the context of individual patients, considering factors such as comorbidities and age. As our understanding of the activity of targeted agents for mRCC increases, we should ensure that these agents are used appropriately to provide patients with optimal treatment benefits. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1391899
- author
- Bellmunt, Joaquim ; Flodgren, Per LU ; Roigas, Jan and Oudard, Stéphane
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- BJU International
- volume
- 104
- pages
- 10 - 18
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000266874000004
- pmid:19388982
- scopus:67650506761
- pmid:19388982
- ISSN
- 1464-4096
- DOI
- 10.1111/j.1464-410X.2009.08563.x
- language
- English
- LU publication?
- yes
- id
- 88321d2b-b41f-4458-8b35-b01fd2b71d4f (old id 1391899)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19388982?dopt=Abstract
- date added to LUP
- 2016-04-04 07:07:28
- date last changed
- 2022-04-15 18:32:04
@article{88321d2b-b41f-4458-8b35-b01fd2b71d4f,
abstract = {{The treatment of metastatic renal cell carcinoma (mRCC) has been changed by the introduction of targeted agents. Consideration of individual patient factors, such as previous treatment and prognostic risk, e.g. according to the Memorial Sloan-Kettering Cancer Center (MSKCC) risk criteria), can assist in ensuring that patients receive appropriate targeted therapies. Available clinical evidence shows sunitinib to be the reference standard of care for the first-line treatment of mRCC in patients at favourable or intermediate prognostic risk according to MSKCC criteria. Combined treatment with bevacizumab plus interferon-alpha can also be considered for the first-line treatment of mRCC in this setting. For the first-line treatment of poor-risk patients, temsirolimus has shown benefit in a phase III study, while sunitinib can also be considered. For second-line treatment in cytokine-refractory patients, sorafenib is recommended based on phase III trial results; sunitinib has also shown activity after failure of cytokine therapy or targeted agents. As well as antitumour activity, the tolerability of targeted agents should be evaluated in the context of individual patients, considering factors such as comorbidities and age. As our understanding of the activity of targeted agents for mRCC increases, we should ensure that these agents are used appropriately to provide patients with optimal treatment benefits.}},
author = {{Bellmunt, Joaquim and Flodgren, Per and Roigas, Jan and Oudard, Stéphane}},
issn = {{1464-4096}},
language = {{eng}},
pages = {{10--18}},
publisher = {{Wiley-Blackwell}},
series = {{BJU International}},
title = {{Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.}},
url = {{http://dx.doi.org/10.1111/j.1464-410X.2009.08563.x}},
doi = {{10.1111/j.1464-410X.2009.08563.x}},
volume = {{104}},
year = {{2009}},
}